#1 Clinical Trials Search in Europe

Pemafibrate

Pemafibrate, a novel drug, is currently being studied in clinical trials for its potential benefits in treating diabetic retinopathy and non-alcoholic fatty liver disease. This article will explore the ongoing research, potential benefits, and implications of using Pemafibrate in these medical conditions.

Table of Contents

What is Pemafibrate?

Pemafibrate is a new medication that belongs to a class of drugs known as fibrates. It is considered a more potent and selective version of an older drug called fenofibrate[1]. Pemafibrate is designed to target a specific protein in the body called peroxisome proliferator-activated receptor alpha (PPAR-α), which plays a crucial role in regulating fat metabolism.

Conditions Treated by Pemafibrate

Pemafibrate is being studied for its potential to treat several conditions related to diabetes and fat metabolism:

  • Diabetic Retinopathy: This is a complication of diabetes that affects the eyes. It occurs when high blood sugar levels damage the blood vessels in the retina (the light-sensitive tissue at the back of the eye), potentially leading to vision loss[1].
  • Diabetic Macular Edema: This is a condition where fluid builds up in the macula (the central part of the retina), causing swelling and potentially affecting central vision[1].
  • Non-Alcoholic Fatty Liver Disease (NAFLD): This is a condition where excess fat accumulates in the liver of people who drink little or no alcohol. It’s often associated with obesity and type 2 diabetes[2].

How Pemafibrate Works

Pemafibrate works by activating the PPAR-α protein in the body. This activation helps to:

  • Reduce the levels of triglycerides (a type of fat) in the blood
  • Potentially slow down the progression of diabetic retinopathy
  • Possibly improve liver function in patients with fatty liver disease

By targeting these areas, pemafibrate aims to address multiple health issues related to diabetes and fat metabolism[1][2].

Dosage and Administration

The dosage and administration of pemafibrate can vary depending on the condition being treated and the specific study. Based on the clinical trials information, here are some examples:

  • For diabetic retinopathy: 0.2 mg taken orally twice daily (BID)[1]
  • For fatty liver disease:
    • High dose: 0.2 mg taken orally twice daily after meals
    • Low dose: 0.1 mg taken orally twice daily after meals[2]

It’s important to note that these dosages are based on clinical trials and may not reflect the final approved dosages if the drug becomes commercially available. Always follow the instructions provided by your healthcare provider.

Ongoing Research and Clinical Trials

Pemafibrate is currently being studied in several clinical trials to evaluate its effectiveness and safety:

  1. PROMINENT-Eye Ancillary Study (Protocol AD): This study is investigating whether pemafibrate can reduce the worsening of diabetic retinopathy in adults with type 2 diabetes[1].
  2. PRESENT Study: This trial is evaluating the effect of pemafibrate on fatty liver in patients with high triglyceride levels and NAFLD, comparing it to fenofibrate[2].

These studies aim to provide more evidence about the potential benefits of pemafibrate in treating various conditions related to diabetes and fat metabolism.

Potential Benefits of Pemafibrate

While research is still ongoing, pemafibrate shows promise in several areas:

  • Diabetic Eye Complications: It may help slow down the progression of diabetic retinopathy and reduce the risk of diabetic macular edema, potentially preserving vision in people with diabetes[1].
  • Liver Health: For patients with non-alcoholic fatty liver disease, pemafibrate might help improve liver function and reduce fat accumulation in the liver[2].
  • Cardiovascular Health: By reducing triglyceride levels, pemafibrate may also have positive effects on heart health, although this is still being studied[1].

It’s important to remember that pemafibrate is still under investigation, and more research is needed to fully understand its benefits and potential side effects. Patients should always consult with their healthcare providers about the latest treatment options for their specific conditions.

Aspect PROMINENT-Eye Ancillary Study PRESENT Study
Primary Condition Diabetic Retinopathy Non-Alcoholic Fatty Liver Disease (NAFLD)
Study Design Randomized, placebo-controlled Multi-center, open-label, three-arm, randomized controlled trial
Pemafibrate Dosage 0.2 mg orally twice daily High dose: 0.2 mg twice daily; Low dose: 0.1 mg twice daily
Comparison Group Placebo Fenofibrate
Primary Outcome Diabetic Retinopathy Worsening or DME Development Change in ALT level

FAQ

  • What is Pemafibrate and how does it work? Pemafibrate is a more potent and selective peroxisome proliferator-activated receptor alpha (PPARα) modulator than fenofibrate. It works by activating PPARα, which may help reduce triglycerides and potentially slow the progression of certain diseases.
  • What medical conditions are being studied with Pemafibrate? Pemafibrate is being studied for its potential benefits in treating diabetic retinopathy, diabetic macular edema, and non-alcoholic fatty liver disease (NAFLD) complicated by high triglyceride levels.
  • How is Pemafibrate administered in these clinical trials? In the trials, Pemafibrate is typically administered orally, twice daily. The dosage varies depending on the study, ranging from 0.1 mg to 0.2 mg tablets taken after meals.
  • What are the potential benefits of Pemafibrate for diabetic retinopathy? The PROMINENT-Eye Ancillary Study aims to assess whether Pemafibrate can reduce the rate of diabetic retinopathy worsening in adults with type 2 diabetes. It may help prevent the onset or slow the progression of diabetic retinopathy.
  • How does Pemafibrate compare to other treatments in these studies? In the NAFLD study, Pemafibrate is being compared to fenofibrate, another fibrate drug. The study aims to evaluate the effect of Pemafibrate on fatty liver in patients with high triglycerides and NAFLD, using fenofibrate as a control.

Ongoing Clinical Trials on Pemafibrate

  • Study on the Effects of Pemafibrate and Tofogliflozin in Patients with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis

    Not recruiting

    1
    Investigated drugs:
    Bulgaria Spain

Glossary

  • Pemafibrate: A novel drug that is a more potent and selective peroxisome proliferator-activated receptor alpha (PPARα) modulator, being studied for its potential benefits in treating various medical conditions.
  • Diabetic Retinopathy (DR): A complication of diabetes that affects the eyes, causing damage to the blood vessels in the retina, which can lead to vision problems and potentially blindness if left untreated.
  • Diabetic Macular Edema (DME): A condition that can occur in people with diabetic retinopathy, where fluid accumulates in the macula (central part of the retina), leading to vision problems.
  • Non-Alcoholic Fatty Liver Disease (NAFLD): A condition where excess fat builds up in the liver of people who drink little or no alcohol, potentially leading to liver damage.
  • Hypertriglyceridemia: A condition characterized by high levels of triglycerides (a type of fat) in the blood, which can increase the risk of heart disease and other health problems.
  • Peroxisome Proliferator-Activated Receptor Alpha (PPARα): A protein that plays a crucial role in regulating metabolism, particularly in the breakdown of fats and reduction of inflammation.
  • Fenofibrate: A medication used to lower cholesterol and triglyceride levels in the blood, belonging to a class of drugs called fibrates.
  • ALT (Alanine Aminotransferase): An enzyme found primarily in the liver; elevated levels in the blood can indicate liver damage or disease.

References

  1. https://clinicaltrials.gov/study/NCT03345901
  2. https://clinicaltrials.gov/study/NCT06623539